{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:26:58Z","timestamp":1793755618672,"version":"4.6.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102219","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:59:08Z","timestamp":1790265548000},"page":"102219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stevens-Johnson syndrome precipitating days after treatment for dostarlimab-induced autoimmune encephalitis: a case report"],"prefix":"10.1016","volume":"67","author":[{"given":"Morgan","family":"Kuchar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayyan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Pigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashlyn","family":"Lipnicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandol","family":"Wolfenbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian Symmes","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.gore.2026.102219_bb0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J. Invest. Dermatol."},{"issue":"19","key":"10.1016\/j.gore.2026.102219_bb0010","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102219_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae186","article-title":"Immune-related encephalitis after immune checkpoint inhibitor therapy","volume":"30","author":"Buckley","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2026.102219_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.gore.2026.102219_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12060773","article-title":"Immune checkpoint inhibitor associated autoimmune encephalitis, rare and novel topic of neuroimmunology: a case report and review of the literature","volume":"12","author":"Gao","year":"2022","journal-title":"Brain Sci."},{"issue":"4","key":"10.1016\/j.gore.2026.102219_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.gore.2026.102219_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002521","article-title":"T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab","volume":"9","author":"Hammond","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.gore.2026.102219_bb0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cea.14134","article-title":"Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?","volume":"52","author":"Hammond","year":"2022","journal-title":"Clin. Exp. Allergy"},{"issue":"9","key":"10.1016\/j.gore.2026.102219_bb0045","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.gore.2026.102219_bb0050","article-title":"Association of Baseline Tumor-Specific Neoantigens and CD8 T-cell infiltration with immune-related adverse events secondary to immune checkpoint inhibitors","volume":"8","author":"Kerepesi","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"23","key":"10.1016\/j.gore.2026.102219_bb0055","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102219_bb0060","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"National Cancer Institute","year":"2017"},{"issue":"4","key":"10.1016\/j.gore.2026.102219_bb0065","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.gore.2026.102219_bb0070","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab","volume":"7","author":"Shah","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.gore.2026.102219_bb0075","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:38:24Z","timestamp":1793752704000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":15,"alternative-id":["S2352578926001992"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102219","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens-Johnson syndrome precipitating days after treatment for dostarlimab-induced autoimmune encephalitis: a case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102219"}}